The European Commission, the Heads of Medicines Agencies and the European Medicines Agency have recently launched an initiative, Accelerating Clinical Trials in the European Union (ACT EU), to transform how clinical trials are initiated, designed and run.

Building on the application of the Clinical Trials Regulation and the launch of the Clinical Trials Information System (CTIS) on 31 January 2022, ACT EU will strengthen the European environment for clinical trials, whilst maintaining the high-level of protection of trial participants, data robustness and transparency. The ACT EU strategy paper recently published lists ten priority actions for 2022/2023, including enabling innovative trial methods, establishing a multi-stakeholder platform and supporting the modernisation of good clinical practice.

Together, they will contribute to achieving the ambitious goals for innovation in clinical trials set out in the European medicines agencies network strategy (EMANS) to 2025 and the European Commission’s Pharmaceutical Strategy.

Discover more by reading the strategy paper here!

Subscribe To Our Newsletter

to keep you up to date on our activities and initiatives

La tua iscrizione non può essere convalidata.
La tua iscrizione è avvenuta correttamente.

We use Brevo as our marketing platform. By clicking below to submit this form, you are aware and accept that the information you have provided will be transferred to Brevo for treatment in accordance with their terms of use
Utilizziamo Brevo come nostra piattaforma di marketing. Cliccando qui sotto per inviare questo modulo, sei consapevole e accetti che le informazioni che hai fornito verranno trasferite a Brevo per il trattamento conformemente alle loro condizioni d'uso

You have Successfully Subscribed!

Pin It on Pinterest

Share This